The market mirrors a developing accentuation on early identification and mediation programs for amblyopia. General wellbeing drives and expanded awareness among guardians and medical services experts add to the early recognizable proof of amblyopia, empowering convenient therapy to boost visual results.
Computerized stages are assuming a critical part in vision evaluating for amblyopia. Versatile applications and PC based devices offer helpful and available strategies for early identification, considering boundless screening drives and adding to the general market pattern of proactive eye wellbeing management.
Continuous examination in amblyopia therapeutics incorporates pharmacological methodologies. Arising patterns include the advancement of prescriptions and drug intercessions pointed toward advancing visual improvement in amblyopic eyes, giving extra choices to treatment past conventional strategies.
The market pattern incorporates a shift towards redid treatment plans for amblyopia patients. Fitting mediations based on individual patient attributes, like age, importance of amblyopia, and related visual conditions, upgrades treatment competency and patient consistency.
The market for amblyopia treatment is extending internationally, determined by expanded admittance to pediatric eye care administrations. Arising economies are seeing an ascent popular for specific eye care for youngsters, adding to the general growth of the amblyopia treatment market.
Advanced health advances are affecting the market, especially in the monitoring and management of amblyopia. Incorporation with advanced stages considers remote monitoring of patient advancement, giving important information to medical services suppliers and upgrading congruity of care.
Telemedicine is becoming progressively important in amblyopia care. Distant counsels, telemonitoring, and virtual treatment meetings give open doors to more available and adaptable consideration delivery, addressing boundaries to normal in-person visits, especially in pediatric cases.
The amblyopia treatment market is ready for proceeded with growth as examination and innovative progressions continue. Developments in vision treatment, pharmacological mediations, and an emphasis on customized treatment approaches are supposed to shape the future scene, giving people upgraded choices for overseeing and further developing vision in instances of amblyopia.
Amblyopia Market Size was valued at USD 4.5 billion in 2021 and is projected to grow from USD 4.68 Billion in 2022 to USD 6.4 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.3% during the forecast period (2023 - 2032). Increasing cases of ophthalmological disorders including refractive errors and cataracts and government funding for ophthalmology research are the key market drivers enhancing the market growth.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Amblyopia is very common in childhood, with a worldwide incidence ranging from 0.2% to 6.2%. According to the journal published in Karger International, the article estimated that 99.2 million people had low vision in 2019, 175.2 million by 2030, and 221.9 million by 2040. This may help in boosting demand of the market.
Several major market players are focused on launching technologically advanced products to treat amblyopia. This is anticipated to boost the amblyopia treatment market during the forecast period. For example, in March 2021, NovaSight received 510(k) clearance from the Food and Drug Administration for CureSight to treat amblyopia. The device helps train the brain to use both eyes simultaneously while the user watches videos through her 3D glasses.
Video games are fast becoming an innovative treatment option for amblyopia. Investors in the amblyopia treatment market are raising awareness of the proper use of video games in young children by improving the brain-eye connection. It has been shown that eye patches may not help the eyes learn to work together. Various companies in the amblyopia treatment market are increasingly focusing on video games to get children and parents on board quickly. However, Lack of skilled professionals and high cost related to its treatment factors restraining the growth of the Amblyopia market revenue.
The Amblyopia market segmentation, based on type, includes Strabismus amblyopia, Refractive amblyopia, Deprivation amblyopia, and Reverse amblyopia. The Strabismus amblyopia segment held the majority share in 2021 in respect to the Amblyopia market revenue. This is primarily owing to the rising numbers of patients suffering from strabismic amblyopia across the globe. Strabismus is the most common cause of amblyopia. Refractive amblyopia was the second largest segment in terms of market share in 2021. The increase in the prevalence of refractive amblyopia is anticipated to drive the segment during the forecast period. According to the American Academy of Ophthalmology, the prevalence of anisometropic amblyopia is about 4.7% in children.
The Amblyopia market segmentation, based on Diagnosis, includes Visual acuity tests, Photo screening, Bruckner test, and others. The visual acuity tests segment dominated the market in 2021 and is projected to be the faster-growing segment during the forecast period, 2022-2030. It is basic and mandatory test required before the amblyopia treatment. Further, Increasing research & development and continuous improvements in the Brückner test is fueling the growth of this segment in the amblyopia market. Hence, rising applications of visual acuity tests for Amblyopia positively impacts the market growth.
The Amblyopia market data has been bifurcated by Treatment into Eye patches, Atropine drops, Glasses, Video game, and Others. The eye patch segment dominated the market in 2021 and is projected to be the faster-growing segment during the forecast period, 2022-2030. This is due to the wearing an eye patch is a simple, cost-effective treatment for lazy eye and it also helps improve vision in the weaker eye. Further, the launch of new eye patches for the treatment of amblyopia is driving demand in this segment. Also, video games are emerging as an innovative treatment options.
March 2021 Novasight received the food and drug administration clearance for CureSight for the treatment of amblyopia. The device trains the brain to use both eyes simultaneously, while the user watches videos through 3D glasses. This initiative has further broadened the growth opportunity for the Amblyopia industry.
In addition, Companies in the amblyopia treatment market are seeing high demand for pure cotton amblyopia eye patches for eyewear to treat children suffering from strabismus amblyopia. To do so, it focus on developing advanced, reusable, pure cotton eye patches for amblyopia. It also develop innovative designs with cartoons in products to attract children.
Figure 2 Amblyopia Market, by Treatment, 2021 & 2030 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Based on End Users, the Amblyopia industry has been segmented into Hospitals & pharmacies, and Ophthalmic clinics. Hospitals & pharmacies held the largest segment share in 2021, owing to the easy availability of treatment facilities. Moreover, the proximity to the skills and awareness of hospitals and pharmacies among end-users underpins a large share of the market.
In addition, the segment of ophthalmology clinics is witnessing a growing consumer awareness of these centers therefore it is expected to grow significantly. Additionally, the company's increasing focus on opening new eye clinics is boosting the growth of the low vision market. New and emerging players are facing competition in the low vision market with an eye on this segment..
By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. Asia-Pacific Amblyopia market accounted for USD 1.899 billion in 2021 and is expected to exhibit a significant CAGR growth during the study period. The region constituted 42.20% share of the market in 2021. This is attributed to the increasing availability of amblyopia treatment technologies across the region. Moreover, increasing penetration of new companies, through mergers and acquisitions, fuels the market in the region.
Further, the major countries studied in the market report are The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3 AMBLYOPIA MARKET SHARE BY REGION 2021 (%)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Amblyopia market accounts for one of the largest market share due to the availability of cutting-edge treatment facilities, government backing for the growth of the healthcare industry, Increase in number of amblyopia cases in Europe is driving the growth of the market in the region. Moreover, High purchasing power among consumers in the region positively influences the growth of the market. Further, the Germany Amblyopia market held the largest market share, and the UK Amblyopia market was the fastest growing market in the European region
The North America Amblyopia Market is expected to grow at the fastest CAGR from 2022 to 2030. This is due to the presence of advanced technologies in the medical industry. Moreover, easy availability of recourses supports the growth of key players and new entrance in the market in this region. Moreover, China Amblyopia market held the largest market share, and the India Amblyopia market was the fastest growing market in the Asia-Pacific region.
Amblyopia Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the Amblyopia market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Amblyopia industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the Amblyopia industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, Amblyopia industry has provided medicine with some of the most significant benefits. The Amblyopia market major player such as Amblyotech, Good-Lite Co., Vivid Vision, Cooper Vision, Johnson & Johnson, Novartis AG, Carl Zeiss, HOYA Corporation, Hilco Vision., and others are working to expand the market demand by investing in research and development activities.
CooperVision, Inc. is a business unit of The Cooper Companies, Inc. It is a soft contact lens manufacturer headquartered in Pleasanton, U.S. The company reorganized into Cooper Laboratories, Cooper Medical Devices, Cooper Dental, Cooper International, and CooperVision. CooperVision offers scientific and technological innovation, operational excellence and close working relationships with eye care professional and customers. In 2019, CooperVision, Inc., acquired Blanchard Contact Lenses, Inc., which helped the company to expand its presence in the specialty segment. This creates more opportunities for CooperVision to partner with eye care professionals, and for them to meet a range of patient needs.
Also, Novartis AG use innovative science and technology to address some of society's most challenging healthcare issues. It develop treatments and innovative ways to deliver to peoples. Its projects includes new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients ly. In 2019, Novartis AG acquired Takeda eye drug for approximately US$ 5.3 Bn, which helped the company to expand its product portfolio.
Key Companies in the Amblyopia market includes
Amblyopia Industry Developments
In October 2021 HOYA Vision Care, announced a partnership with Orbis International, which is a organization that mentors, trains, and inspires local eye care professionals to save sight in their communities. The main aim behind this strategic partnership is to bridge the vision care gap around the world.
April 2020 Novartis announced the complete acquisition of the USA-based software start-up Amblyotech Inc. and will work with Ubisoft and McGill University to develop the acquired digital technology for the treatment of amblyopia. Amblyotech is a clinical-stage digital therapeutics company involved in the treatment and diagnosis of amblyopia and other several eye-related disorders.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)